Subscribe to RSS
Download PDF
DOI: 10.1055/s-0038-1628541
Metformin bei Antipsychotikainduzierter Amenorrhoe
Metformin in the treatment of antipsychotic induced amenorrheaPublication History
eingegangen am:
10 May 2013
angenommen am:
23 May 2013
Publication Date:
23 January 2018 (online)
Zusammenfassung
Die Antipsychotika(AP)-induzierte Amenorrhoe ist mit einer Prävalenz von 9 bis 12% eine häufige unerwünschte Arzneimittelwirkung (UAW) bei der pharmakologischen Behandlung von Patientinnen mit Erkrankungen aus dem schizophrenen Formenkreis. Gegenwärtig sind für diese UAW keine standardisierten Behandlungsmöglichkeiten verfügbar. Im Hinblick auf metabolische und endokrinologische Analogien zwischen der AP-induzierten Amenorrhoe und dem polyzystischen Ovarialsyndrom (PCOS) ergibt sich eine mögliche therapeutische Option durch Metformin. Metformin führt in vielen Fällen von PCOS zu einer Wiederherstellung des Menstruationszyklus. Eine chinesische Arbeitsgruppe konnte im Rahmen einer placebokontrollierten, randomisierten und doppelblinden Studie durch die Gabe von Metformin bei 66% an Schizophrenie ersterkrankten Patientinnen mit AP-induzierter Amenorrhoe eine Wiederherstellung der Menstruation erzielen. Der genaue Mechanismus ist noch ungeklärt, jedoch könnte Metformin eine Behandlungsoption bei der AP-induzierten Amenorrhoe darstellen.
Summary
Antipsychotic (AP)-induced amenorrhea shows a prevalence of 9 to 12% and thus is a frequent adverse drug reaction (ADR) in the pharmacologic treatment of female patients with schizophrenia. Currently, no standardized treatment options for this particular ADR are available. Taking into account similarities regarding metabolic and endocrinologic aspects between the AP-induced amenorrhea and the polycystic ovary syndrome (PCOS) there is, however, a treatment option with metformin. Treatment with metformin allows to recover the menstrual cycle in many cases of PCOS. Within a recent placebo-controlled, randomized, and double-blind clinical study of a Chinese group it was possible to recover the menstruation cycle in 66% of the female patients with first-episode schizophrenia and AP-induced amenorrhea. The underlying mechanism has not yet been clarified. However, metformin might be a treatment option for AP-induced amenorrhea.
-
Literatur
- 1 Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 Suppl 1: 1-93.
- 2 Malik P, Kemmler G, Hummer M, RiecherRoessler A, Kahn RS, Fleichhacker WW. EUFEST Study Group. Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenias Trial. J Clin Psychopharmacol 2011; 31: 274-80.
- 3 Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, Chen JD, Li LH. Metformin addition attenuates olanzapin-induced weight gain in drug-naive first-episode schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 2008; 165: 352-8.
- 4 Wu RR, Jin H, Gao K, Twamley EW, Ou JJ, Shao P, Wang J, Guo XF, Davis JM, Chan PK, Zhao JP. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2012; 169: 813-21.
- 5 Canuso CM, Goldstein JM, Wojcik J, Dawson R, Brandman D, Klibanski A, Schildkraut JJ, Green AI. Antipsychotic medication, prolactin elevation and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res 2002; 111: 11-20.
- 6 Palomba S, Falbo A, Zullo F, Orio Jr F. Evidencebased and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009; 30: 1-50.
- 7 Kaufmann M, Serban DC, Scharl A. (Hrsg.) Die Gynäkologie. 3. Auflage. Berlin: Springer; 2013
- 8 Dunaif A. Insulin resistance an the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
- 9 Ortega-González C, Cardoza L, Coutino B, Hidddalgo R, Arteaga-Troncoso G, Parra A. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. J Endocrinol 2005; 184: 233-9.
- 10 Creanga AA, Bradley HM, McCormick C, Witkop CT. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gynecol 2008; 111: 959-68.
- 11 Palomba S, Falbo A. Metformin in therapy naive patients with polycystic ovary syndrome. Hum Reprod Update 2008; 14: 193.
- 12 Tankova T. Current indications for metformin therapy. Rom J Intern Med 2003; 41: 215-25.
- 13 Newcomer JW. Second-generation (atypical) antipsychotic and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 Suppl 1: 1-93.
- 14 Newall H, Myles N, Ward PB, Samaras K, Shiers D, Curtis J. Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. Int Clin Psychopharmacol 2011; 27: 69-75.
- 15 Prentice DS, Deakin FW. Role of neuroleptic drugs and organic mechanism in the aetiology of menstrual irregularities. Schizophrenie Res 1992; 06: 114.
- 16 Savage DB, Semple RK, Chatterjee VK, Wales JK, Ross RJ, O´Rahilly S. A clinical approach to severe insulin resistance. Endocr Dev 2007; 122-32.
- 17 Fitzgerald PB, Scaffidi A, Morris MJ, de Castellar AR, Kulkarni J. The relationschip of changes in leptin, neuropeptide Y and reproduktive hormones to antipsychotic induced weight gain. Hum Psychopharmacol 2003; 18: 551-7.